Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Apogee TherapeuticsAPGE +0.26%22 EV-to-OCF is -38.99 as of Aug. 09, 2026. GuruFocus rates APGE with a GF Score™ of 22/100. The stock has 3 warning signs investors should review. Among 1,407 Biotechnology companies, Apogee Therapeutics ranks better than 89.77% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Apogee Therapeutics's Enterprise Value is $9,145.68 Mil.
Apogee Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $-234.54 Mil. Therefore, Apogee Therapeutics's EV-to-OCF for today is -38.99.
The historical rank and industry rank for Apogee Therapeutics's EV-to-OCF or its related term are showing as below:
APGE'
s EV-to-OCF Range Over the Past 10 Years
Min: -38.99 Med: 0 Max: -38.99
Current: -38.99
During the past 4 years, the highest EV-to-OCF of Apogee Therapeutics was -38.99. The lowest was -38.99. And the median was .
APGE's EV-to-OCF is ranked better than 89.77% of 1407
companies
in the Biotechnology industry
Industry Median: -3.45
vs APGE: -38.99
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Apogee Therapeutics's PE Ratio (TTM) for today is calculated as:
Apogee Therapeutics's share price for today is $134.84.
Apogee Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.330.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Apogee Therapeutics EV-to-OCF Related Terms
Apogee Therapeutics EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Apogee Therapeutics's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Apogee Therapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apogee Therapeutics EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Apogee Therapeutics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Apogee Therapeutics's EV-to-OCF falls into.
Apogee Therapeutics's current Enterprise Value is $9,145.68 Mil.
Apogee Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-234.54 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apogee Therapeutics (APGE) has a EV-to-OCF of -38.99 as of Aug. 09, 2026. According to the industry distribution chart, Apogee Therapeutics ranks #144 out of 1407 companies in the Biotechnology industry, placing it in the top 10.2%.
Is Apogee Therapeutics' EV-to-OCF too high?
Apogee Therapeutics' current EV-to-OCF is -38.99. Based on the distribution chart, Apogee Therapeutics ranks #144 out of 1407 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Apogee Therapeutics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Apogee Therapeutics' EV-to-OCF compare to CORT and KRYS?
According to the Biotechnology industry distribution chart, Apogee Therapeutics ranks #144 out of 1407 companies for EV-to-OCF. This places Apogee Therapeutics in the top 10% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Apogee Therapeutics's current EV-to-OCF is -38.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apogee Therapeutics stock overvalued right now?
Apogee Therapeutics (APGE) has a current EV-to-OCF of -38.99. The current EV-to-OCF is -38.99. Apogee Therapeutics' overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Apogee Therapeutics (APGE), the current EV-to-OCF is -38.99 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
22GF Score
Get the complete analysis for APGE
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
APGE has been successfully added to your 
